4.66
0.16 (3.56%)
| Penutupan Terdahulu | 4.50 |
| Buka | 4.57 |
| Jumlah Dagangan | 1,435,711 |
| Purata Dagangan (3B) | 1,337,670 |
| Modal Pasaran | 644,189,056 |
| Harga / Jualan (P/S) | 44.09 |
| Harga / Buku (P/B) | 0.610 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2025 - 4 Aug 2025 |
| Margin Operasi (TTM) | -4,568.83% |
| EPS Cair (TTM) | -4.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -94.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.21% |
| Nisbah Semasa (MRQ) | 6.79 |
| Aliran Tunai Operasi (OCF TTM) | -415.08 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -310.09 M |
| Pulangan Atas Aset (ROA TTM) | -23.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -44.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Vir Biotechnology, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 1.50 |
|
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 22.66% |
| % Dimiliki oleh Institusi | 79.23% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gates Foundation | 30 Sep 2024 | 1,559,142 |
| Ikarian Capital, Llc | 31 Mar 2025 | 1,068,062 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (Goldman Sachs, 350.64%) | Beli |
| Median | 17.50 (275.54%) | |
| Rendah | 14.00 (Needham, 200.43%) | Beli |
| Purata | 17.50 (275.54%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 5.06 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 22 May 2025 | 14.00 (200.43%) | Beli | 4.61 |
| 12 May 2025 | 14.00 (200.43%) | Beli | 5.30 | |
| Goldman Sachs | 17 Apr 2025 | 21.00 (350.64%) | Beli | 5.50 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |